To include your compound in the COVID-19 Resource Center, submit it here.

Remicade infliximab regulatory update

FDA's Gastrointestinal Drugs Advisory Committee backed approval of Remicade infliximab for 3 of the 5 claims Johnson & Johnson proposed for pediatric ulcerative colitis (UC). The panel unanimously supported approval for induction of clinical

Read the full 343 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE